Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors

Area of Science:

• Microbiology and Infectious Diseases
• Drug Discovery and Development
• Bacterial Pathogenesis

Background:

• Multidrug-resistant (MDR) bacterial infections pose a significant global health threat, necessitating novel therapeutic strategies.
• Existing antibiotics face challenges due to bacterial resistance mechanisms, including efflux pumps and virulence factors.
• The Pseudomonas aeruginosa type III secretion system (T3SS) and resistance-nodulation-cell division (RND) efflux pumps are key targets for combating bacterial infections.

Purpose of the Study:

• To review the development of novel small-molecule adjunctive agents designed to overcome MDR bacterial infections.
• To explore agents targeting the T3SS of Pseudomonas aeruginosa and RND efflux pumps in Enterobacteriaceae.
• To highlight how these adjunctive agents can improve the efficacy of conventional antibacterials.

Main Methods:

• Literature review focusing on the design and mechanism of action of small-molecule adjunctive agents.
• Analysis of T3SS inhibitors and RND efflux pump inhibitors.
• Evaluation of the combined efficacy of adjunctive agents with existing antibiotics.

Main Results:

• Development of novel small-molecule agents targeting bacterial virulence (T3SS) and resistance (RND efflux pumps).
• T3SS inhibition protects host cells from bacterial toxins, thereby supporting the host immune response.
• RND efflux pump inhibition restores susceptibility to antibiotics, broadening treatment options.

Conclusions:

• Small-molecule adjunctive agents targeting T3SS or RND efflux pumps represent a promising strategy to combat MDR bacterial infections.
• These agents can be co-administered with existing antibiotics to enhance their therapeutic efficacy.
• Further development of these novel agents is crucial for addressing the growing challenge of antimicrobial resistance.